Oklahoma 2024 Regular Session

Oklahoma Senate Bill SB1344 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
	3	+	SB1344 HFLR Page 1
	4	+	BOLD FACE denotes Committee Amendments. 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
3	28
4		-	An Act
5		-	ENROLLED SENATE
	29	+	HOUSE OF REPRESENTATIVES - FLOOR VERSION
	30	+
	31	+	STATE OF OKLAHOMA
	32	+
	33	+	2nd Session of the 59th Legislature (2024)
	34	+
	35	+	ENGROSSED SENATE
6	36		BILL NO. 1344 By: Rosino of the Senate
7	37
8	38		and
9	39
10		-	West (Josh)~~, Munson,~~ and
11		-	~~McDugle of~~ the House
	40	+	West (Josh) and Munson of
	41	+	the House
12	42
13	43
14	44
15	45
16	46
17	47		An Act relating to nonopioid alternatives; directing
18	48		specified agencies to seek certain funding
19	49		opportunities and provide certain assistance with
20	50		opioid grant awards; defining term; granting certain
21	51		protection to nonopioid drugs relating to Medicaid
22	52		drug formulary; prohibiting certain denial of
23	53		coverage; providing certain construction ; amending 74
24	54		O.S. 2021, Section 30.5, as amended by Section 1,
25	55		Chapter 75, O.S.L. 2022 (74 O.S. Supp. 2023, Section
26	56		30.5), which relates to definitions used in the
27	57		Political Subdivisions Opioid Abatement Grants Act;
28	58		broadening approved purposes; providing for
29	59		codification; and providing an effective date .
30	60
31	61
32	62
33	63
34	64
35		-	SUBJECT: Nonopioid alternatives
36		-
37	65		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
38		-
39	66		SECTION 1. NEW LAW A new section of law to be codified
40	67		in the Oklahoma Statutes as S ection 2-402 of Title 43A, unless there
41	68		is created a duplication in numbering, reads as follows:
42	69
	70	+	SB1344 HFLR Page 2
	71	+	BOLD FACE denotes Committee Amendments. 1
	72	+	2
	73	+	3
	74	+	4
	75	+	5
	76	+	6
	77	+	7
	78	+	8
	79	+	9
	80	+	10
	81	+	11
	82	+	12
	83	+	13
	84	+	14
	85	+	15
	86	+	16
	87	+	17
	88	+	18
	89	+	19
	90	+	20
	91	+	21
	92	+	22
	93	+	23
	94	+	24
	95	+
43	96		The Department of Mental Health and Substance Abuse Services,
44	97		the State Department of Health, and the Oklahoma Health Care
45	98		Authority shall:
46		-
47		-
48		-	ENR. S. B. NO. 1344 Page 2
49	99		1. Collaborate to seek funding opportunities for educational
50	100		and health care services related to nonopioid alternatives; and
51		-
52	101		2. Assist, upon request, political subdivisions that receive
53	102		opioid grant awards under the Political Subdivisions Opioid
54	103		Abatement Grants Act with t he development and implementation of
55	104		educational and health care services related to nonopioid
56	105		alternatives.
57		-
58	106		SECTION 2. NEW LAW A new section of law to be codified
59	107		in the Oklahoma Statutes as Section 5031 of Title 63, unless there
60	108		is created a duplication in numbering, reads as follows:
61		-
62	109		A. As used in this section, “contracted entity” has the same
63	110		meaning as provided by Section 4002.2 of Title 56 of the Oklahoma
64	111		Statutes.
65		-
66	112		B. In establishing and maintaining the formulary for the stat e
67	113		Medicaid program, the Oklahoma Health Care Authority shall ensure
68	114		that no nonopioid drug approved by th e United States Food and Drug
69	115		Administration (FDA) for the treatment or management of pain shall
70	116		be disadvantaged or discouraged by either the Authorit y or a
71	117		contracted entity with respect to coverage on the formulary relative
72	118		to any opioid or narcotic drug for the treatment or management of
73	119		pain.
74	120
	121	+	SB1344 HFLR Page 3
	122	+	BOLD FACE denotes Committee Amendments. 1
	123	+	2
	124	+	3
	125	+	4
	126	+	5
	127	+	6
	128	+	7
	129	+	8
	130	+	9
	131	+	10
	132	+	11
	133	+	12
	134	+	13
	135	+	14
	136	+	15
	137	+	16
	138	+	17
	139	+	18
	140	+	19
	141	+	20
	142	+	21
	143	+	22
	144	+	23
	145	+	24
	146	+
75	147		C. When a contracted provider prescribes a n FDA-approved
76	148		nonopioid drug for the treatment or management of pain, the
77	149		Authority or a contracted entity shall not deny coverage of the
78	150		nonopioid drug in favor of a n opioid drug.
79		-
80	151		D. This section does not preclude opioid drugs from being
81	152		preferred over other opioid drugs or nonopioid drugs from being
82	153		preferred over other nonopioid drugs.
83		-
84	154		SECTION 3. AMENDATORY 74 O.S. 2021, Sect ion 30.5, as
85	155		amended by Section 1, Chapter 75, O.S.L. 2022 (74 O.S. Supp. 2023,
86	156		Section 30.5), is amended to read as follows:
87		-
88	157		Section 30.5. As used in the Political Su bdivisions Opioid
89	158		Abatement Grants Act:
90		-
91		-
92		-	ENR. S. B. NO. 1344 Page 3
93	159		1. “Approved purpose” and “approved purposes” mean evidence-
94	160		based, forward-looking strategies, programming and services used to:
95		-
96	161		a. expand the availability of treatment for individuals
97	162		affected by opioid use disorde rs, co-occurring
98	163		substance use disorders and mental health issues,
99		-
100	164		b. develop, promote and provide evidence-based opioid use
101	165		prevention strategies,
102		-
103	166		c. provide opioid use disorder and co -occurring substance
104	167		use disorder avoidance and awareness education,
105		-
106	168		d. decrease the oversupply of licit and illicit opioids,
107		-
108	169		e. support recovery from addiction services perfor med by
109	170		qualified and appropriately licensed providers,
110	171
	172	+	SB1344 HFLR Page 4
	173	+	BOLD FACE denotes Committee Amendments. 1
	174	+	2
	175	+	3
	176	+	4
	177	+	5
	178	+	6
	179	+	7
	180	+	8
	181	+	9
	182	+	10
	183	+	11
	184	+	12
	185	+	13
	186	+	14
	187	+	15
	188	+	16
	189	+	17
	190	+	18
	191	+	19
	192	+	20
	193	+	21
	194	+	22
	195	+	23
	196	+	24
	197	+
111	198		f. treat opioid use, abuse and disorders including early
112	199		intervention screening, counseling and support,
113		-
114	200		g. support individuals in treatment and recovery from
115	201		opioid use, abuse and dis order,
116		-
117	202		h. provide programs or services to connect individuals
118	203		with opioid use, abuse or disorder, or who are at risk
119	204		of developing opioid use disorder, co -occurring
120	205		substance use disorder and mental health issues, with
121	206		treatment and counseling programs and services,
122		-
123	207		i. address the needs of individuals who are involved, or
124	208		who are at risk of becoming involved, in the criminal
125	209		justice system due to opioid use, abuse or dis order
126	210		through programs or services in municipal and county
127	211		criminal judicial systems inc luding prearrest and
128	212		postarrest diversion programs, pretrial services and
129	213		drug or recovery courts,
130		-
131	214		j. address the needs of pregnant or parenting women with
132	215		opioid use, abuse or disorder and their families,
133		-
134		-
135		-	ENR. S. B. NO. 1344 Page 4
136	216		k. address the needs of parents and caregivers caring for
137	217		babies with neonatal abstinence syndrome,
138		-
139	218		l. support efforts to prevent overprescribing and ensure
140	219		appropriate prescribing and dispensing of opioids,
	220	+
	221	+	SB1344 HFLR Page 5
	222	+	BOLD FACE denotes Committee Amendments. 1
	223	+	2
	224	+	3
	225	+	4
	226	+	5
	227	+	6
	228	+	7
	229	+	8
	230	+	9
	231	+	10
	232	+	11
	233	+	12
	234	+	13
	235	+	14
	236	+	15
	237	+	16
	238	+	17
	239	+	18
	240	+	19
	241	+	20
	242	+	21
	243	+	22
	244	+	23
	245	+	24
141	246
142	247		m. support efforts to discourage or prevent misuse of
143	248		opioids including the oversupply of licit an d illicit
144	249		opioids,
145		-
146	250		n. support efforts to prevent or reduce overdose deaths
147	251		or other opioid-related harms including through
148	252		increased availability and distribution of na loxone
149	253		and other drugs that treat overdoses for use by first
150	254		responders, persons who have experienced an overdose
151	255		event, families, schools, community -based service
152	256		providers, social workers and other members of the
153	257		public,
154		-
155	258		o. reimburse or fund law enforcem ent and emergency
156	259		responder expenditures relating to the opioid epidemic
157	260		including costs of responding to emergency medical or
158	261		police calls for service, equipment, treatment or
159	262		response alternatives, mental health response training
160	263		and training for law enf orcement and emergency
161	264		responders as to appropriate practices and precautions
162	265		when dealing with opioids o r individuals who are at
163	266		risk of opioid overdose or death,
164		-
165	267		p. reimburse attorney fees and allowable expenses
166	268		directly related to opioid litigation incu rred as part
167	269		of legal services agreements entered into before May
168	270		21, 2020,
	271	+
	272	+	SB1344 HFLR Page 6
	273	+	BOLD FACE denotes Committee Amendments. 1
	274	+	2
	275	+	3
	276	+	4
	277	+	5
	278	+	6
	279	+	7
	280	+	8
	281	+	9
	282	+	10
	283	+	11
	284	+	12
	285	+	13
	286	+	14
	287	+	15
	288	+	16
	289	+	17
	290	+	18
	291	+	19
	292	+	20
	293	+	21
	294	+	22
	295	+	23
	296	+	24
169	297
170	298		q. support efforts to provide leadership, planning and
171	299		coordination to abate the opioid epidemic through
172	300		activities, programs or strategies for prevention and
173	301		recovery models inclu ding regional intergovernmental
174	302		efforts and not-for-profit agency support,
175		-
176	303		r. support education of youths regarding the dangers of
177	304		opioid use, abuse and addiction,
178		-
179		-	ENR. S. B. NO. 1344 Page 5
180		-
181	305		s. fund training relative to any approved purpose,
182		-
183	306		t. monitor, surveil and evaluate opioid u se, abuse or
184	307		disorder, or
185		-
186	308		u. provide educational and health care services related
187	309		to nonopioid treatment alternatives, or
188		-
189	310		v. provide opioid abatement as identified by the Oklahoma
190	311		Opioid Abatement Board as consistent with the purpose
191	312		of the Political Subdi visions Opioid Abatement Grants
192	313		Act.
193		-
194	314		Provided that, such strategies, programming and services occurred on
195	315		or after January 1, 2015;
196		-
197	316		2. “Board” means the Oklahoma Opioid Abatement Board;
198		-
199	317		3. “Eligible participant ” means any political subdivision
200	318		impacted by the opioid crisis;
201		-
202	319		4. “Nonapproved purpose” and “nonapproved purposes ” mean
203	320		strategies, programming and services not falling within the
	321	+
	322	+	SB1344 HFLR Page 7
	323	+	BOLD FACE denotes Committee Amendments. 1
	324	+	2
	325	+	3
	326	+	4
	327	+	5
	328	+	6
	329	+	7
	330	+	8
	331	+	9
	332	+	10
	333	+	11
	334	+	12
	335	+	13
	336	+	14
	337	+	15
	338	+	16
	339	+	17
	340	+	18
	341	+	19
	342	+	20
	343	+	21
	344	+	22
	345	+	23
	346	+	24
	347	+
204	348		definition of approved purpose or approved purposes as defined in
205	349		this section;
206		-
207	350		5. “Opioid funds” means all monetary amounts obtained through a
208	351		settlement or judgment by the Attorney General on behalf of this
209	352		state related to opioid litigation involving pharmaceutical supply
210	353		chain participants including the Purdue Political Subdivisions Fund
211	354		but excluding all other fund s received pursuant to the Purdue
212	355		Settlement Agreement;
213		-
214	356		6. “Opioid grant awards” means grants funded from the Oklahoma
215	357		Opioid Abatement Revolving Fund, awarded pursuant to the provisions
216	358		of the Political Subdivisions Opioid Abatement Grants Act;
217		-
218	359		7. “Pharmaceutical supply chain ” means the process and channels
219	360		through which controlled substances are manufactu red, marketed,
220	361		promoted, distributed or dispensed;
221		-
222		-
223		-	ENR. S. B. NO. 1344 Page 6
224	362		8. “Pharmaceutical supply chain participant ” means any entity
225	363		that engages in or has engaged in the manufacture, marketing,
226	364		promotion, distribution or dispensing of an opioid analgesic;
227		-
228	365		9. “Political subdivision” and “political subdivisions ” have
229	366		the same meaning as provided in subparagraphs a, b, c and d of
230	367		paragraph 11 of Section 152 of Title 51 of t he Oklahoma Statutes;
231		-
232	368		10. “Purdue Political Subdivision Fund ” means the Twelve
233	369		Million Five Hundred Thou sand Dollars ($12,500,000.00) plus any
234	370		interest accrued thereon received from the Revive Oklahoma Health
235	371		Foundation consisting of funds from the Purdue Settlement Agreement
	372	+
	373	+	SB1344 HFLR Page 8
	374	+	BOLD FACE denotes Committee Amendments. 1
	375	+	2
	376	+	3
	377	+	4
	378	+	5
	379	+	6
	380	+	7
	381	+	8
	382	+	9
	383	+	10
	384	+	11
	385	+	12
	386	+	13
	387	+	14
	388	+	15
	389	+	16
	390	+	17
	391	+	18
	392	+	19
	393	+	20
	394	+	21
	395	+	22
	396	+	23
	397	+	24
	398	+
236	399		designed for distribution to political subdivisions which have
237	400		executed a release of legal claims as required by the Purdue
238	401		Settlement Agreement; and
239		-
240	402		11. “Purdue Settlement Agreement ” means the settlement
241	403		agreement entered into by th is state and Purdue Pharma L.P., Purdue
242	404		Pharma, Inc. and the Purdue Frederick Company on March 26, 2019, and
243	405		approved by the Court on April 2, 2019.
244		-
245	406		SECTION 4. This act shall become effective November 1, 2024.
246	407
247		-
248		-	ENR. S. B. NO. 1344 Page 7
249		-	Passed the Senate the 1 4th day of March, 2024.
250		-
251		-
252		-
253		-	Presiding Officer of the Senate
254		-
255		-
256		-	Passed the House of Representatives the 17th day of April, 2024.
257		-
258		-
259		-
260		-	Presiding Officer of the House
261		-	of Representatives
262		-
263		-	OFFICE OF THE GOVERNOR
264		-	Received by the Office of the Governor this _______ _____________
265		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
266		-	By: _________________________________
267		-	Approved by the Governor of the State of Oklahoma this _______ __
268		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
269		-
270		-	_________________________________
271		-	Governor of the State of Oklahoma
272		-
273		-
274		-	OFFICE OF THE SECRETARY OF STATE
275		-	Received by the Office of the Secretary of State this _______ ___
276		-	day of _________________ _, 20 _______, at _______ o'clock _______ M.
277		-	By: _______________________________ __
	408	+	COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS AND BUDGET, dated
	409	+	04/11/2024 - DO PASS.